Experts said that US public health is now at risk after the CDC vaccine panel voted against the widespread recommendation for the hepatitis B vaccine at birth.
The decision is based on outcomes from the Phase II NOBILITY and Phase III REGENCY trials.
The ARPA-H CATALYST programme aims to transform preclinical drug safety prediction using human-based models.
The deal is anticipated to be finalised in the first quarter of 2026, pending the fulfilment of all closing conditions.
The partnership is intended to expedite R&D in small and large-molecule analysis.
Opinions were divided on the continued use of the hepatitis B vaccine in a paediatric population.
